Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.85), $0.09 better than the analyst estimate of ($0.94). Revenue for the quarter came in at $21.6 million versus the consensus estimate of $22.75 million.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.